Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Can a wristband replace the blood pressure cuff?

NCT ID NCT05780710

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study compares a new optical blood pressure monitor worn on the wrist to the standard arm cuff for home use. About 35 adults with high blood pressure (stage 1 or 2) will use both devices while taking medication. The goal is to see if the wrist monitor is as accurate and easy to use for managing blood pressure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 35 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2023

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

21 to 85 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Adult subjects aged 21 to 85 years old 2. Subjects that can read and speak French 3. Subjects that own a smart phone that uses either the iOS or Android operating system 4. Hypertensive Stage 1 (SBP 140-159 mmHg or DBP 90-99 mmHg) or Hypertensive Stage 2 (SBP 160-179 mmHg or DBP 100-109 mmHg) or for subjects aged \> 65yo SBP ≥160 mmHg, 5. Naive of antihypertensive drugs at the inclusion in the study (no antihypertensive drugs taken in the last 3 months before Visit 1) and during the conduct of the study apart from the study drugs 6. Subjects agreeing to attend all 4 on-site visits and follow study procedures 7. Subjects that have signed the informed consent form Exclusion Criteria: 1. Subjects have contraindications to the study drugs 2. Subjects with Hypertension Stage 3 (SBP/DBP \>180/110 mmHg) 3. Subjects with orthostatic hypotension (a 20 mmHg decrease in systolic BP, or 10 mmHg decrease in diastolic BP when measured in the standing position after a 1-minute waiting period) 4. Subjects who are likely to be unable to perform the HBPM required for the study within the designated time frame (7 to 11 a.m. and 4 to 9 p.m.). 5. Subjects having medical interventions or taking treatments during the study that could have an impact on their BP 6. For GROUPS 1 and 2 only: Subjects with target organ damage (left ventricular hypertrophy observed on ECG, and/ or, albumin/creatinine ratio in urine ≥3.5 mg/mmol) 7. Subjects with tachycardia (heart rate at rest \> 120bpm) 8. Subjects with atrial fibrillation 9. Cardio myopathy (FE\<40%) 10. Severe valvular disease 11. Implanted devices such as a pacemaker or defibrillator 12. Subjects with diabetes 13. Subjects with renal dysfunctions (eGFR \< 45mL/min/1.73 m2 for patients between 21-85 yo) 14. Subjects with hyper-/hypothyroidism 15. Subjects with pheochromocytoma 16. Subjects with Raynaud's disease 17. Subjects with an arteriovenous fistula 18. Women in known pregnancy 19. Subjects with trembling and shivering 20. Subjects with lymphoedema 21. Low or elevated potassium level: threshold ≤3.5 mmol/L or ≥4.8 mmol/L 22. Presence of an intravascular device 23. Subjects with exfoliative skin diseases 24. Subjects with arm paralysis 25. Subjects with arm amputation 26. Subjects with upper arm circumference \< 22cm or \> 42cm 27. Subjects with wrist circumference \> 23cm 28. Subjects with non-standard circadian rhythm, including shift workers and night workers 29. Subjects who have received a mastectomy.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hypertension are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • CHUV

    RECRUITING

    Lausanne, 1011, Switzerland

  • CHVR

    WITHDRAWN

    Sion, Valais, 1951, Switzerland

  • HUG

    TERMINATED

    Geneva, Canton of Geneva, 1205, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.